Trial Profile
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Intec Pharma
- 12 Nov 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 28 Nov 2014 New trial record
- 19 Dec 2009 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov record.